Merck KGaA signs DNA damage response cancer deal with Artios PharmaGermany’s Merck KGaA has joined with UK-based Artios Pharma in a potential multi-billion dollar deal to investigate novel Share XMerck KGaA signs DNA damage response cancer deal with Artios Pharmahttps://pharmaphorum.com/news/merck-kgaa-signs-dna-damage-response-cancer-deal-with-artios-pharma/
UK’s Artios raises $84m to further DDR drug researchManagement team led development of AZ’s PARP drug Lynparza Share XUK’s Artios raises $84m to further DDR drug researchhttps://pharmaphorum.com/news/uks-artios-raises-84m-to-further-ddr-drug-research/